Open Access
Aponermin: First Approval
1
Springer Nature, Auckland, New Zealand
|
Publication type: Journal Article
Publication date: 2024-03-05
scimago Q1
wos Q1
SJR: 3.362
CiteScore: 26.2
Impact factor: 14.4
ISSN: 00126667, 11791950
PubMed ID:
38441805
Pharmacology (medical)
Abstract
Aponermin (沙艾特) is a recombinant circularly permuted human tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) developed by Beijing Sunbio Biotech (a wholly owned subsidiary of Wuhan Hiteck Biological Pharma CO., LTD) for the treatment of multiple myeloma. Aponermin binds to and activates the death receptors 4 and/or 5 on tumour cells, triggering intracellular caspase reactions and inducing apoptosis, thereby exerting antitumor effects. In November 2023, aponermin in combination with thalidomide and dexamethasone received its first approval in China for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. This article summarizes the milestones in the development of aponermin leading to this first approval for relapsed or refractory multiple myeloma.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Scientific Reports
3 publications, 18.75%
|
|
|
International Journal of Molecular Sciences
1 publication, 6.25%
|
|
|
RSC Medicinal Chemistry
1 publication, 6.25%
|
|
|
Nature Reviews Drug Discovery
1 publication, 6.25%
|
|
|
Antibody Therapeutics
1 publication, 6.25%
|
|
|
Molecular Pharmaceutics
1 publication, 6.25%
|
|
|
Russian Chemical Reviews
1 publication, 6.25%
|
|
|
The Innovation
1 publication, 6.25%
|
|
|
Blood Science
1 publication, 6.25%
|
|
|
International Journal of Biological Macromolecules
1 publication, 6.25%
|
|
|
Journal of Controlled Release
1 publication, 6.25%
|
|
|
Medical Oncology
1 publication, 6.25%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
|
|
|
Springer Nature
5 publications, 31.25%
|
|
|
Elsevier
4 publications, 25%
|
|
|
MDPI
1 publication, 6.25%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 6.25%
|
|
|
Oxford University Press
1 publication, 6.25%
|
|
|
American Chemical Society (ACS)
1 publication, 6.25%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 6.25%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 6.25%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 6.25%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
16
Total citations:
16
Citations from 2024:
16
(100%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s40265-024-02004-9
UR - https://doi.org/10.1007/s40265-024-02004-9
TI - Aponermin: First Approval
T2 - Drugs
AU - Dhillon, Sohita
PY - 2024
DA - 2024/03/05
PB - Springer Nature
SP - 459-466
IS - 4
VL - 84
PMID - 38441805
SN - 0012-6667
SN - 1179-1950
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2024_Dhillon,
author = {Sohita Dhillon},
title = {Aponermin: First Approval},
journal = {Drugs},
year = {2024},
volume = {84},
publisher = {Springer Nature},
month = {mar},
url = {https://doi.org/10.1007/s40265-024-02004-9},
number = {4},
pages = {459--466},
doi = {10.1007/s40265-024-02004-9}
}
Cite this
MLA
Copy
Dhillon, Sohita. “Aponermin: First Approval.” Drugs, vol. 84, no. 4, Mar. 2024, pp. 459-466. https://doi.org/10.1007/s40265-024-02004-9.